<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4489">
  <stage>Registered</stage>
  <submitdate>9/06/2014</submitdate>
  <approvaldate>9/06/2014</approvaldate>
  <nctid>NCT02165397</nctid>
  <trial_identification>
    <studytitle>Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia</studytitle>
    <scientifictitle>iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PCYC-1127-CA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Waldenström's Macroglobulinemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ibrutinib
Treatment: drugs - Placebo
Treatment: drugs - Rituximab

Experimental: Treatment Arm A (Ibrutinib + Rituximab) - Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1 Rituximab: 375 mg/m2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.

Experimental: Treatment Arm B (Placebo + Rituximab) - Placebo: 3 capsules of placebo orally administered daily beginning from Day 1 Rituximab: 375 mg/m2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.

Experimental: Treatment Arm C (Ibrutinib) - Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1


Treatment: drugs: Ibrutinib
Subjects will receive 420 mg of Ibrutinib orally. Other Name: PCI-32765

Treatment: drugs: Placebo
Subjects will receive placebo capsules orally.

Treatment: drugs: Rituximab
Drug: rituximab Subjects will receive rituximab 375mg/m2 intravenously Other Name: Rituxan

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival</outcome>
      <timepoint>Up to 3 years after last subject is randomized</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Response Rate (ORR)</outcome>
      <timepoint>At disease progression, up to 3 years after last subject is randomized</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematological improvement measured by hemoglobin</outcome>
      <timepoint>At disease progression, up to 3 years after last subject is randomized</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to next Treatment (TTnT)</outcome>
      <timepoint>End-of-treatment visit, up to 3 years after last subject is randomized</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival</outcome>
      <timepoint>At disease progression, up to 3 years after last subject is randomized</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants with adverse events as a measure of safety and tolerability within each treatment arm</outcome>
      <timepoint>Up to 30 days following the last dose of study drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Eligibility Criteria for the Randomized Study (Arm A and Arm B)

        

          -  Untreated or previously treated for Waldenström's macroglobulinemia. Previously
             treated subjects must have either documented disease progression or had no response
             (stable disease) to the most recent treatment regimen.

          -  Centrally confirmed clinicopathological diagnosis of WM

          -  Measurable disease defined as serum monoclonal IgM &gt;0.5 g/dL.

          -  Symptomatic disease meeting at least 1 of the recommendations from the Second
             International Workshop on Waldenström Macroglobulinemia for requiring treatment

          -  Hematology and biochemical values within protocol-defined limits

          -  Men and women = 18 years of age.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of =2.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known involvement of the central nervous system by WM.

          -  Disease that is refractory to the last prior rituximab-containing therapy defined as
             either

               -  Relapse after the last rituximab-containing therapy &lt;12 months since last dose of
                  rituximab, OR

               -  Failure to achieve at least a MR after the last rituximab-containing therapy. If
                  the subject meets this exclusion criterion and therefore is excluded from the
                  main randomized study, participation in the non randomized substudy (Arm C) may
                  be considered

          -  Rituximab treatment within the last 12 months before the first dose of study drug.

          -  Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or to any
             component of rituximab.

          -  Prior exposure to ibrutinib or other BTK inhibitors.

          -  Known bleeding disorders (eg, von Willebrand's disease) or hemophilia.

          -  History of stroke or intracranial hemorrhage within 12 months prior to enrollment.

          -  Any uncontrolled active systemic infection.

          -  Any life-threatening illness, medical condition, or organ system dysfunction that, in
             the investigator's opinion, could compromise the subject's safety or put the study
             outcomes at undue risk.

          -  Currently active, clinically significant cardiovascular disease

          -  Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor

        Eligibility Criteria for Open-label Substudy Treatment Arm C

        The Inclusion/Exclusion criteria for the substudy (Arm C) are identical to those described
        above for the randomized study but, to be eligible, subjects need to be considered
        refractory to the last prior rituximab-containing therapy defined as either

          -  Relapse after the last rituximab-containing therapy &lt;12 months since last dose of
             rituximab, OR

          -  Failure to achieve at least a MR after the last rituximab-containing therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>181</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,SA,VIC</recruitmentstate>
    <hospital>The Canberra Hospital - Garran</hospital>
    <hospital>Concord Repartriation General Hospital - Concord</hospital>
    <hospital>Flinders Medical Center - Bedford Park</hospital>
    <hospital>Peter MacCallum Cancer Center - Melbourne</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>05042 - Bedford Park</postcode>
    <postcode>3000 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bouches-du-Rhône</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Finistère</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Loire-Atlantique</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Meurthe-et-Moselle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nord</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Puy-de-Dôme</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rhône</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Créteil</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinland-Pfalz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Saarland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bremen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Achaia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Attiki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castilla y León</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dorset</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmacyclics LLC.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Janssen Research &amp; Development, LLC</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and efficacy of Ibrutinib in combination
      with Rituximab in subjects with Waldenström's Macroglobulinemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02165397</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>